See the DrugPatentWatch profile for mylotarg
Are any Mylotarg (gemtuzumab ozogamicin) biosimilars available?
No. Mylotarg is not a small-molecule drug that has “biosimilar” versions in the usual sense. It is an antibody-drug conjugate (ADC)—a complex biologic therapy—so the products marketed as exact “biosimilars” are not available the way they are for simpler monoclonal antibodies. Based on the standard biosimilar pathway, there are no widely approved “Mylotarg biosimilars” in the public biosimilar sense.
What would count as an “Mylotarg biosimilar”?
An ADC would generally need:
- The same or highly similar antibody component,
- A comparable linker and payload,
- Comparable drug-to-antibody ratio (DAR) and other structural/quality attributes,
- Evidence it matches safety and effectiveness in clinical trials.
Because Mylotarg’s structure is tightly defined and technically complex, replacement products typically come through separate “follow-on” development rather than being straightforward biosimilar copies.
Are there alternatives if I’m trying to switch treatments?
If the goal is access, supply, or cost rather than a strict “biosimilar,” clinicians usually look at:
- Other AML therapies in the same treatment setting, or
- Other ADCs with different targets/payloads.
If you tell me your indication (for example, AML in first remission vs relapsed/refractory), line of therapy, and region/country, I can narrow which available alternatives are most comparable.
Who makes Mylotarg, and is patent protection part of the reason no biosimilars exist?
Mylotarg’s market exclusivity and patent landscape can affect when follow-on products enter. You can check the current status of related patents and exclusivity information on DrugPatentWatch.com: https://www.drugpatentwatch.com/